Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
48.9M
-
Shares change
-
+3.5M
-
Total reported value, excl. options
-
$718M
-
Value change
-
+$58.2M
-
Put/Call ratio
-
0.75
-
Number of buys
-
66
-
Number of sells
-
-60
-
Price
-
$14.70
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q1 2024
158 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2024.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.9M shares
of 77.1M outstanding shares and own 63.33% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.58M shares), Redmile Group, LLC (4.48M shares), BAKER BROS. ADVISORS LP (3.88M shares), Deep Track Capital, LP (3M shares), STATE STREET CORP (2.73M shares), ARK Investment Management LLC (2.64M shares), VANGUARD GROUP INC (2.58M shares), MORGAN STANLEY (2.53M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.2M shares), and DEUTSCHE BANK AG\ (1.5M shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.